2.1
Tafamidis (Vyndaqel, Pfizer) is indicated for 'the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR‑CM)'.
2 Information about tafamidis
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for tafamidis.
Price
2.3
The list price is £10,685 for 30 capsules of 61 mg tafamidis (excluding VAT; BNF online, accessed April 2024).
2.4
The company has a commercial arrangement. This makes tafamidis available to the NHS with a discount. The size of the discount is commercial in confidence.